Cadent has developed a strong pipeline of medicines for
movement-related diseases and cognitive disorders, with candidates rapidly advancing into the clinic.
Cadent has discovered compounds that modulate SK Channels, calcium-sensitive potassium channels that play a central role in maintaining regular neuronal firing. In people with spinocerebellar ataxia (SCA) and essential tremor (ET), the neurons of the cerebellum have lost rhythmicity and regularity, resulting in the loss of motor control, impacting mobility and fine motor function.
Cadent’s lead compound for the treatment of SCA and ET increases the calcium sensitivity of SK Channels. By changing the calcium sensitivity, potassium current flows at lower calcium concentrations, resulting in a restoration of neuronal firing regularity, and improvements in locomotor function.
AFFECTED BY SCA WORLDWIDE
10 MILLION PEOPLE
AFFECTED BY ET IN THE UNITED STATES
Spinocerebellar ataxia or SCA is a genetic degenerative neurological condition that affects approximately 6,000 people in the United States. Patients are readily identified through genetic testing and most often carry genetic abnormalities called “poly-q expansions,” similar to those found in patients with Huntington’s disease. The disease is progressive and over time, results in ongoing damage to the cerebellum, the part of the brain that regulates motor control and balance.
Essential tremor is a neurological disorder characterized by uncontrollable shaking or tremor in different parts of the body, including the head, arms, hands, neck and chin. It is the most common movement disorder affecting 10 million people in the US alone, though there have been no improvements in standard of care in more than 40 years.
The National Ataxia Foundation is dedicated to improving the lives of persons affected by Ataxia through support, education, and research.
The International Essential Tremor Foundation provides hope to the essential tremor (ET) community worldwide through awareness, education, support, and research.
Cadent is developing a medicine designed to resolve NMDAr (N-methyl-D-aspartate receptor) hypofunction in people with schizophrenia, with the goal of moving beyond symptom management to restoring cognitive function.
Proper functioning of NMDArin the brain is critical for learning, memory and the ability to form new neuronal connections (neuroplasticity). In people with schizophrenia, these receptors are dysregulated which is related to cognitive impairment experienced by these patients. Cadent’s medicine is designed to positively modulate the NMDAr reversing NMDAr hypofunction and restoring cognitive function.
2.2 MILLION PEOPLE
AFFECTED BY SCHIZOPHRENIA
Schizophrenia affects nearly 2.2 million people in the US alone. Symptoms normally begin between the ages of 16 and 20, and can impact perception of reality, emotional responsiveness and cognition. Current drug therapies for schizophrenia help alleviate the psychotic symptoms while cognitive impairment remains untreated.
NAMI, the National Alliance on Mental Illness, is the nation’s largest grassroots mental health organization dedicated to building better lives for the millions of Americans affected by mental illness.
Cadent has entered into an exclusive license and collaboration agreement with Novartis to develop a medicine that modulates NR2B-containing NMDA receptors for the treatment of treatment resistant depression. This medicine is currently in Phase 1 clinical studies.